These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16084286)

  • 1. Newer paradigms in renal replacement therapy: will they alter cardiovascular outcomes?
    Kundhal K; Pierratos A; Chan CT
    Cardiol Clin; 2005 Aug; 23(3):385-91. PubMed ID: 16084286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sleep apnea and daytime sleepiness in end-stage renal disease.
    Hanly P
    Semin Dial; 2004; 17(2):109-14. PubMed ID: 15043611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased chemosensitivity and improvement of sleep apnea by nocturnal hemodialysis.
    Beecroft JM; Duffin J; Pierratos A; Chan CT; McFarlane P; Hanly PJ
    Sleep Med; 2009 Jan; 10(1):47-54. PubMed ID: 18226958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep disorders in end-stage renal disease: 'Markers of inadequate dialysis'?
    Perl J; Unruh ML; Chan CT
    Kidney Int; 2006 Nov; 70(10):1687-93. PubMed ID: 16969388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of nocturnal hemodialysis on sleep apnea in ESRD patients.
    Hanly P; Chan C; Pierratos A
    Nephrol News Issues; 2003 Jun; 17(7):19-21. PubMed ID: 12847958
    [No Abstract]   [Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep.
    Chan CT; Hanly P; Gabor J; Picton P; Pierratos A; Floras JS
    Kidney Int; 2004 Feb; 65(2):661-5. PubMed ID: 14717939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients.
    Zoccali C; Benedetto FA; Tripepi G; Cambareri F; Panuccio V; Candela V; Mallamaci F; Enia G; Labate C; Tassone F
    Kidney Int; 1998 Apr; 53(4):1078-84. PubMed ID: 9551420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nocturnal hypoxemia: a neglected cardiovascular risk factor in end-stage renal disease?
    Zoccali C; Mallamaci F; Tripepi G
    Blood Purif; 2002; 20(1):120-3. PubMed ID: 11803169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional and emerging cardiovascular risk factors in end-stage renal disease.
    Zoccali C; Mallamaci F; Tripepi G
    Kidney Int Suppl; 2003 Jun; (85):S105-10. PubMed ID: 12753278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep apnoea and nocturnal hypoxaemia in dialysis patients: mere risk-indicators or causal factors for cardiovascular disease?
    Zoccali C
    Nephrol Dial Transplant; 2000 Dec; 15(12):1919-21. PubMed ID: 11096133
    [No Abstract]   [Full Text] [Related]  

  • 12. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    Bratisl Lek Listy; 2004; 105(10-11):368-73. PubMed ID: 15658577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients.
    Zoccali C; Mallamaci F; Tripepi G; Benedetto FA
    Nephrol Dial Transplant; 2001 Jan; 16(1):70-7. PubMed ID: 11208996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease in uremic patients on hemodialysis.
    Lazarus JM; Lowrie EG; Hampers CL; Merrill JP
    Kidney Int Suppl; 1975 Jan; (2):167-75. PubMed ID: 1099301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Benefits of Extended-Time Nocturnal Hemodialysis.
    Roumeliotis A; Roumeliotis S; Chan C; Pierratos A
    Curr Vasc Pharmacol; 2021; 19(1):21-33. PubMed ID: 32234001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients.
    Righetti M; Ferrario GM; Milani S; Serbelloni P; La Rosa L; Uccellini M; Sessa A
    Med Sci Monit; 2003 Apr; 9(4):PI19-24. PubMed ID: 12709680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why do patients sleep on dialysis?
    Gul A; Aoun N; Trayner EM
    Semin Dial; 2006; 19(2):152-7. PubMed ID: 16551294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.